NeoGraph Analytics
Life SciencesGlobal2026 – 2032

Pharmacogenomics Market Size, Share & Forecast 2026-2032

Pharmacogenomics: $6.82B in 2026 to $10.01B by 2032 at 6.6%. The FDA's 692-row labelling table and Medicare's panel rate test the published range.

Revenue, 2026

$6.8B

Forecast, 2032

$10.0B

CAGR, 2026-2032

6.6%

Report Coverage

Global

Code: pharmacogenomics-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

Pharmacogenomics is the market where the checkable evidence and the published forecasts point in opposite directions. Estimates for 2025 run from $5.7 billion to $19.24 billion — a 3.38x spread — and 2032 endpoints from $10.0 billion to $42.29 billion, a 4.23x spread. One publisher revised its own figure for 2025 from $7.3 billion to $5.7 billion between editions, a 22% restatement of a historical year. We publish the lowest published series, P&S Intelligence's: $6.82 billion in 2026 rising to $10.01 billion by 2032 at 6.6%, with both ends from that house's own numbers. Two registers decide the question. The FDA's Table of Pharmacogenomic Biomarkers in Drug Labeling, content current as of 12 August 2026, contains 692 rows covering 439 distinct drug products when enumerated — the count every forecast's narrative invokes. Against it, roughly 53 active ingredients carry CPIC Level A guidance, the evidence tier MolDX coverage criteria demand: 12.1% of the 439. And Medicare's clinical laboratory fee schedule rate for CPT 81418, the multi-gene panel code, is $917.08, so a $19.24 billion market implies 20.98 million panels a year — 30.3% of every Medicare beneficiary, annually, for a genotype that never changes. Payer non-coverage is the restraint. There is no Medicare national coverage determination for pharmacogenomic panels at all, the 2025 NGS MAC determination narrowed the qualifying panel definition rather than widening it, and commercial policy is narrower still. Every published CAGR in this market is a bet that coverage loosens, and none of them says so.

02

Key Highlights

1

Headline

$6.82 billion in 2026 to $10.01 billion in 2032 at 6.6%, both ends from P&S Intelligence's own published series

2

Published 2025 estimates span 3.38x ($5.7B-$19.24B) and 2032 endpoints span 4.23x ($10.0B-$42.29B)

3

The FDA's Table of Pharmacogenomic Biomarkers in Drug Labeling, current as of 12 August 2026, contains 692 rows covering 439 distinct drug products — counted directly

4

About 53 active ingredients carry CPIC Level A guidance, the tier payers recognise: 12.1% of the 439 labelled drugs the forecasts cite

5

At Medicare's $917.08 rate for CPT 81418, a $19.24 billion market implies 20.98 million panels a year — 30.3% of every Medicare beneficiary annually, for a genotype that never changes

6

There is no Medicare national coverage determination for pharmacogenomic panels; NGS MAC's L39995, effective 12 July 2025, narrowed the qualifying panel definition

7

One publisher restated its own 2025 figure from $7.3 billion to $5.7 billion between editions — a 22% revision of a historical year

03

Market Overview

Market Context

Pharmacogenomics sits at the junction of two systems that do not talk to each other. On one side is the regulatory record, which is unusually good: the FDA maintains and publishes a labelling table that anyone can count, and CPIC publishes graded gene-drug pair assignments with explicit evidence tiers. On the other side is reimbursement, where there is no national Medicare policy, coverage varies by Medicare Administrative Contractor jurisdiction, and commercial payers routinely class high-volume CYP tests as not medically necessary or investigational. The market exists in the gap. It is not technology-limited — genotyping a panel of pharmacogenes is cheap and commoditised, and the assay vendors are the same companies that supply every other genomics market. It is not evidence-limited in the narrow sense either, since the high-consequence pairs are established and already standard of care. It is limited by who pays, and by the structural problem that the benefit of a pharmacogenomic test accrues over a patient's lifetime while the cost falls on whoever happens to be the payer that year. That is why psychiatry, where the patient often pays, is the one application with real commercial volume, and why integrated health systems are the setting where pre-emptive testing actually happens.

Pharmacogenomics has the most checkable evidence base of any market in this corpus and one of the widest spreads: published 2025 sizings run from $5.7 billion to $19.24 billion, a 3.38x gap, and 2032 endpoints from $10.0 billion to $42.29 billion. The FDA publishes the register that settles it. Its Table of Pharmacogenomic Biomarkers in Drug Labeling, current as of 12 August 2026, contains 692 rows covering 439 distinct drug products — the number every forecast cites. But only about 53 active ingredients carry CPIC Level A guidance, the tier payers actually recognise, which is 12.1% of the 439. Dividing the highest published base by Medicare's $917.08 rate for the multi-gene panel code implies 20.98 million panels a year, or 30.3% of every Medicare beneficiary annually, for a genotype that never changes. We publish the lowest published series and name payer non-coverage as the restraint the forecasts omit.

Market Stage

Growth

Adoption Level

Concentrated in psychiatry and oncology; not routine

Key Trends

The FDA labelling register keeps growing and keeps being misread: 692 table rows covering 439 distinct drug products as of 12 August 2026, of which only a subset direct any prescribing action at allPayer coverage is narrowing, not widening: NGS MAC's local coverage determination L39995, effective 12 July 2025, requires a panel of at least six genes including CYP2C19 and CYP2D6 with duplication and deletion analysis, and there is still no Medicare national coverage determination for pharmacogenomic panelsCommercial policy is narrower than Medicare: Cigna's pharmacogenetic testing policy lists CPT 81225 (CYP2C19) as not medically necessary, and a CareSource Medicaid policy classes several high-volume CYP tests as experimental and investigationalOncology companion diagnostics are being counted as pharmacogenomics in some published series and not in others — QYResearch sizes theranostics and companion diagnostics alone at $12.59 billion for 2024, more than three of the whole-market estimatesOne publisher revised its own historical base by 22% between editions, from $7.3 billion to $5.7 billion for the same year 2025, which is an admission that the base was modelled rather than measuredFDA's laboratory-developed tests rule was vacated on 31 March 2025 and not appealed, so pharmacogenomic panels remain CLIA-regulated services — removing a compliance cost several 2024-vintage forecasts had priced in, while changing nothing about reimbursement
04

Market Forecast & Data

Market Growth Forecast
2026-2032 · CAGR 6.6%

Base Year (2026)

$6.8B

Forecast (2032)

$10.0B

CAGR (2026-2032)

6.6%

Market size by year, 2026-2032, in USD Billion.
YearMarket size ($ Billion)
2026Base year$6.82B
2027$7.27B
2028$7.75B
2029$8.26B
2030$8.81B
2031$9.39B
2032$10.01B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. Modelled at a constant 6.6% CAGR between P&S Intelligence's published 2025 base and 2032 endpoint. How these figures are produced.
Forecast Analysis

We publish 6.6%, the lowest rate in the set, applied to the lowest dated base, and even that is a forecast about coverage policy rather than about technology. P&S Intelligence's series closes on itself — $6.4 billion for 2025 compounded at 6.6% over seven years gives $10.01 billion against its published $10.0 billion for 2032 — which is why we can use both of its endpoints rather than extrapolating one. The houses publishing 10.4% and 11.9% are making the same bet at higher conviction, and the grounding arithmetic shows how high. At Medicare's $917.08 panel rate, the top of the published range requires 20.98 million panel tests a year today and 46.11 million by 2032, against a Medicare population of roughly 69.3 million and a US population near 341 million. No repeat testing is clinically indicated, so those volumes have to come from new patients, and the policy record runs the other way: the NGS MAC determination effective 12 July 2025 tightened the panel definition, and commercial policies have not broadened. The identifiable upside is not a rate at all but a set of discrete events — new CPIC Level A pairs, each of which enlarges the reimbursable set directly; clinical decision support reaching the point of prescription; and payers who bear lifetime cost adopting pre-emptive panels. Readers should treat 6.6% as the no-policy-change path and model the alternatives as step functions, not as a steeper curve.

05

Market Dynamics

  • A growing, checkable regulatory evidence base: 439 distinct drug products now carry pharmacogenomic information in FDA labelling, up from counts in the low hundreds a decade ago
  • Psychiatry, where response and tolerability to antidepressants and antipsychotics vary with CYP2D6 and CYP2C19 metabolism, and where cash-pay and commercial panel volume exists independently of Medicare
  • Known high-consequence pairs where testing is already standard of care: HLA-B before abacavir, DPYD before capecitabine and fluorouracil, TPMT and NUDT15 before thiopurines, CYP2C19 before clopidogrel
  • Falling genotyping cost, which makes a six-or-more gene panel cheaper to run than sequential single-gene tests and is the reason CPT 81418 panel billing has displaced gene-by-gene billing
  • Pre-emptive panel programmes in integrated health systems, where one genotype is stored and queried at each subsequent prescription rather than ordered per drug
06

Market Segmentation

By Type

  • Genotyping
  • SNP identification
  • Pharmacogenetic testing services
  • Software and clinical decision support

By End User

  • Clinical and reference laboratories
  • Hospitals and clinics
  • Pharmaceutical companies
  • Academic and research institutions

By Application

  • Psychiatry and neurology
  • Oncology
  • Cardiovascular disease
  • Infectious disease
  • Pain management
07

Competitive Landscape

L

Laboratory Corporation of America Holdings

Burlington, North Carolina, United States

One of the two national reference laboratories through which most US pharmacogenomic panel volume is billed. Does not break out pharmacogenomic testing revenue in its segment reporting, so no share can be stated and we assign none.

Offers multi-gene pharmacogenomic panels billed under CPT 81418 alongside single-gene codes, with coverage determined jurisdiction by jurisdiction under Medicare Administrative Contractor local coverage determinations rather than a national policy.

Q

Quest Diagnostics Incorporated

Secaucus, New Jersey, United States

The other national reference laboratory with scale in pharmacogenomic panel testing. No pharmacogenomic revenue split is disclosed.

Runs pharmacogenomic panels as CLIA-regulated laboratory services. Its position depends more on payer contracting and clinical-decision-support integration than on assay technology, which is commoditised.

M

Myriad Genetics, Inc.

Salt Lake City, Utah, United States

The most visible specialist in psychiatric pharmacogenomics, the single application where panel testing has achieved meaningful commercial volume. Reports product-level revenue in its filings but publishes no market share.

GeneSight psychotropic panel, positioned on CYP2D6 and CYP2C19 metabolism and antidepressant selection. Psychiatry is the application where cash-pay and commercial volume exists independently of Medicare coverage, which is why it dominates the germline pharmacogenomic testing that actually happens.

T

Thermo Fisher Scientific Inc.

Waltham, Massachusetts, United States

Supplies the genotyping platforms and pharmacogenomic assay panels that laboratories run, rather than the testing service. Reports no pharmacogenomics line, so its position is not sizeable from filings.

Provides targeted genotyping arrays and PCR-based pharmacogenomic panels. Positioned upstream of the testing market: its revenue grows with panel volume regardless of which laboratory performs the test.

I

Illumina, Inc.

San Diego, California, United States

Present where pharmacogenomics is delivered by sequencing rather than targeted genotyping. FY2025 revenue was $4.34 billion across all applications with no pharmacogenomic split disclosed.

Sequencing platforms and consumables used for pharmacogene panels and for extracting pharmacogenomic calls from broader genomic data. Relevant to the market's long-run direction, since a single sequencing run can yield a pharmacogenomic profile as a by-product.

O

OneOme, LLC

Minneapolis, Minnesota, United States

Private; revenue not disclosed. Competes on the clinical-decision-support layer rather than the assay, which is where this market's value increasingly sits.

RightMed pharmacogenomic panel and associated prescribing-support software, developed with Mayo Clinic. Named because a stored genotype creates no clinical value unless the prescribing system surfaces it, and that layer is not counted in any published market size.

08

Recent Developments

26
2026U.S. Food and Drug Administration

Updated the Table of Pharmacogenomic Biomarkers in Drug Labeling, with content current as of 12 August 2026; enumeration on 16 October 2026 counted 692 table rows covering 439 distinct drug products, with the table noting that labelling for some but not all listed products includes specific actions to be taken based on the biomarker.

26
2026Clinical Pharmacogenetics Implementation Consortium

Updated its gene-drug pair level assignments on 28 July 2026; a 2026 analysis of that list evaluated 53 active ingredients carrying CPIC Level A guidance, the evidence tier that MolDX criteria require for coverage of gene-specific pharmacogenomic testing.

25
2025National Government Services (NGS Medicare Administrative Contractor)

Issued local coverage determination L39995 for pharmacogenomic testing, effective 12 July 2025, covering panel testing in Minnesota, Wisconsin, Illinois, New York and New England only where the panel includes at least six genes including CYP2C19 and CYP2D6 with duplication and deletion analysis.

25
2025Association for Molecular Pathology

Obtained an order from U.S. District Judge Sean D. Jordan on 31 March 2025 vacating FDA's laboratory-developed tests final rule in its entirety, on the ground that such tests are not devices under the Federal Food, Drug, and Cosmetic Act; FDA did not appeal, leaving pharmacogenomic panels regulated as CLIA laboratory services under CMS.

09

Regulatory Landscape

FDA Table of Pharmacogenomic Biomarkers in Drug Labeling (content current as of 12 August 2026): 692 rows covering 439 distinct drug products. The table's own scope note states that a single representative product is listed per dosage form, salt or combination, and that labelling for some but not all listed products includes specific actions to be taken based on the biomarker information. It is a labelling register, not a testing mandate.Clinical Laboratory Improvement Amendments (CLIA), administered by CMS: pharmacogenomic panels are laboratory-developed tests validated and run in CLIA-certified laboratories, with CAP accreditation the practical additional requirement for payer acceptance.No Medicare national coverage determination exists for pharmacogenomic panel testing. Coverage is set by Medicare Administrative Contractor local coverage determinations. NGS MAC's L39995, effective 12 July 2025, covers panel testing in Minnesota/Wisconsin/Illinois and New York/New England only where the panel includes at least six genes including CYP2C19 and CYP2D6 with duplication and deletion analysis; under MolDX criteria, gene-specific testing is covered only where the gene-drug pair carries CPIC Level A or B evidence or appears in FDA labelling.CPT 81418 is the multi-gene pharmacogenomic panel code, defined as a drug metabolism or pharmacogenomics genomic sequence analysis panel that must include testing of at least six genes. Its Medicare clinical laboratory fee schedule national rate is $917.08.Commercial and Medicaid coverage is narrower than Medicare. Cigna's pharmacogenetic testing policy lists CPT 81225 (CYP2C19) among codes considered not medically necessary, and a CareSource Ohio Medicaid policy classes several high-volume CYP tests as experimental and investigational.FDA's laboratory-developed tests final rule was vacated in its entirety on 31 March 2025 and not appealed within the 60-day window, so the CLIA regime administered by CMS remains operative. This removes a prospective compliance cost from pharmacogenomic testing without changing its reimbursement.
10

Research Methodology

Secondary research

  • U.S. FDA, Table of Pharmacogenomic Biomarkers in Drug Labeling, content current as of 08/12/2026; enumerated 16 October 2026: 692 rows, 439 distinct drug products
  • CPT 81418 Medicare clinical laboratory fee schedule national rate of $917.08, as reproduced in Kentucky's 2026 Clinical Diagnostic Laboratory Fee Schedule and West Virginia Medicaid's schedule effective 01/04/2025-31/03/2026
  • NGS MAC local coverage determination L39995, pharmacogenomic testing, effective 12 July 2025
  • Clinical Pharmacogenetics Implementation Consortium level assignments, list updated 28 July 2026; 53 active ingredients with CPIC Level A guidance per a 2026 analysis
  • CMS Medicare enrolment 2025 — approximately 69.3 million beneficiaries, about 20.3% of the US population (via USAFacts aggregation of CMS data)
  • P&S Intelligence, Pharmacogenomics Market Size & Share Analysis (2025-2032), report 12295, December 2024 — $6.1B (2024), $6.4B (2025), $10.0B (2032), 6.6%
  • IMARC Group, Pharmacogenomics Market Report 2026-2034, report SR112026A4396, last updated 02 June 2026 — $9.2B (2025) to $17.6B (2034), 7.25%
  • Global Market Insights, pharmacogenomics market, 2025-2034 and 2026-2035 editions — $7.3B and $5.7B for the same year 2025
  • Cigna coverage policy MM 0500, Pharmacogenetic Testing; CareSource Ohio Medicaid policy AD-1342 (effective 01/04/2024)
  • ClinicalTrials.gov API v2, query.term='pharmacogenomic', retrieved 16 October 2026: 737 registered studies
  • Association for Molecular Pathology v. FDA, order vacating the laboratory-developed tests final rule, 31 March 2025

Validation: The headline uses one house's own published base and its own published endpoint: P&S Intelligence states $6.4 billion for 2025, $10.0 billion for 2032 and 6.6% over 2025-2032, and that series closes on itself (6.4 x 1.066^7 = 10.01). The 2026 base of $6.82 billion is derived by advancing the 2025 figure one year at the same rate, and is labelled as interpolation. Two grounding calculations were run against public registers. First, the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling, content current as of 12 August 2026, was enumerated on 16 October 2026 and contains 692 rows covering 439 distinct drug products; against that, roughly 53 active ingredients carry CPIC Level A guidance, the tier MolDX coverage criteria require, which is 12.1% of the 439 — the gap between the register the forecasts cite and the subset payers reimburse. Second, published market sizes were divided by Medicare's $917.08 clinical laboratory fee schedule rate for CPT 81418, the multi-gene pharmacogenomic panel code, to obtain implied annual panel volumes: $6.4 billion implies 6.98 million panels, $9.2 billion implies 10.03 million, and $19.24 billion implies 20.98 million. Against approximately 69.3 million Medicare beneficiaries and a US population near 341 million, 20.98 million panels a year is 30.3% of every beneficiary annually for a genotype that never changes and need never be repeated, which rules that figure out as reimbursed-testing revenue; 6.98 million panels is 2.0% of the US population per year, which is demanding but reachable given cash-pay psychiatric volume. These are plausibility and ratio tests, not market estimates: they rule the high end out and the low end in without establishing the correct size. The divisor is one US payer's rate for one code, reproduced from state fee-schedule documents rather than the CMS quarterly file; the 53-ingredient CPIC count and the Medicare enrolment figure are from secondary sources; and no register publishes global pharmacogenomic test volume. Regional, country and segment shares are published as empty or as plain strings because the single source offering them presents no method; no vendor market share is published because none is disclosed.

11

Strategic Takeaways

Count the FDA table yourself before accepting a forecast's premise. It holds 692 rows and 439 distinct drug products as of 12 August 2026 — a labelling register, not a testing mandate, and most entries direct no action.

The reimbursable market is roughly an eighth of the labelled market. About 53 active ingredients carry CPIC Level A guidance against 439 labelled drug products, and MolDX coverage criteria follow CPIC, not FDA labelling alone.

Divide any published size by Medicare's $917.08 panel rate before believing it. The top of the published range implies testing 30% of all Medicare beneficiaries every year, for a genotype that never changes.

Check whether a published figure folds in oncology companion diagnostics. One publisher sizes that sub-scope alone at $12.59 billion, more than three of the whole-market estimates.

Watch coverage policy, not technology. There is no Medicare national coverage determination for these panels, the most recent local determination narrowed rather than widened eligibility, and every published CAGR is a bet that this reverses.

12

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.